Downloadable Slides From Rallying the Troops: Optimizing the Use of Checkpoint Inhibitors in NSCLC

Downloadable Slides From Rallying the Troops: Optimizing the Use of Checkpoint Inhibitors in NSCLC

View Activity

Activity Features

Downloadable Slides

Activity Overview

View downloadable slides from our live meeting series for clinicians who treat and manage veterans with lung cancer. Get the latest updates on immunotherapeutic treatment options approved by the US Food and Drug Administration and adverse event management in patients with early-stage and advanced non-small cell lung cancer (NSCLC).

Provider

This activity is provided by prIME Oncology.

Support

This educational activity is supported by grants from AstraZeneca and Merck and Co, Inc.

Featured Expert

  • Corey Carter, MD, John P. Murtha Cancer Center
    Walter Reed National Military Medical Center, National Cancer Institute/National Institutes of Health, Bethesda, Maryland, United States
  • Naiyer Rizvi, MD, New York-Presbyterian Hospital, Columbia University Medical Center, New York, New York, United States

Featured Topic

Optimizing the Use of Checkpoint Inhibitors in NSCLC

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Discuss the mechanisms of action of checkpoint inhibitors used in the treatment of lung cancer
  • Design optimal strategies for the treatment of NSCLC that incorporate the use of checkpoint inhibitors
  • Select the appropriate strategy for managing/mitigating side effects

Enduring Material From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Carter has disclosed that he has no financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rizvi has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Lilly, Merck, Novartis, Pfizer, and Roche. He also has ownership interest in ARMO Biosciences and Gritstone Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Kristin Tomlinson, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships